posted
Hmmmm, where's the bottom? I had an order in this morning to buy some more at $18.50, but I cancelled it when I went out to run errands. Not sure this is the end of the slide yet.
-------------------- "Great Day for Up!"....Dr. Seuss
IP: Logged |
quote:Originally posted by Machiavelli: this one gapped up too high ... it has nowhere to go now but down for a massive "correction" ... think about taking your profits peeps... you can always buy back in later on... <shrugs> i could be wrong though... just don't get too greedy.. MM's will short it sooner or later...
-------------------- Let the world change you... And you can change the world.
quote:Originally posted by Livinonklendathu: 50% fib on the daily is around $14.41, might bounce there like it did at the 38% which was around $17.
Give it up... till if and when it bounces off of RSI 50 and reverses... i predicted this one was overbought and would correct itself.. much like I say the same thing with JSDA... when they are overbought like that .. a "correction" is almost always in the horizon...
-------------------- Let the world change you... And you can change the world.
posted
oops!....... Wednesday May 9, 7:09 am ET FDA Requests Additional Clinical Data on Effectiveness of Dendreon's Provenge Cancer Drug
SEATTLE (AP) -- Biotech drug maker Dendreon Corp. said Wednesday the FDA has requested more clinical data on the effectiveness of its prostate cancer treatment, Provenge, delaying the drug's approval.
ADVERTISEMENT click here The company received an "approvable" letter on Tuesday from the agency that also sought more information on the chemistry, manufacturing and controls of its application. Dendreon said it is seeking clarification on what kind of efficacy data the FDA needs, but believes it can supply the chemistry and manufacturing data promptly.
In late March, an FDA advisory committee reviewed Dendreon's application and agreed 17 to 0 that the submitted data showed Provenge was reasonably safe and 13 to 4 that the drug was shown to be effective.
"Given our strong belief in the survival benefit and safety profile of Provenge, coupled with the positive outcome of the advisory committee meeting, we are disappointed that this decision will cause a delay in the availability of Provenge for patients who suffer from advanced prostate cancer," said Mitchell H. Gold, president and chief executive of Dendreon.
Prostate cancer is the most common non-skin cancer in the U.S. and the third most common cancer worldwide. More than 1 million men in the U.S. have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007.
Dendreon has said about 95 percent of prostate cancer cells contain an antigen called prostatic acid phosphatase, or PAP. Provenge is a new kind of cancer treatment designed to help a man's immune cells recognize those cells that carry PAP as foreign and attack them.
Provenge has been studied in a double-blind, placebo-controlled Phase 3 study that showed that a group of men with asymptomatic, metastatic prostate cancer who received Provenge lived an average of 4.5 months longer than those taking placebo. For the men taking Provenge, the study showed a 41 percent overall reduction in the risk of death, and 34 percent of patients were alive 36 months after treatment, compared with just 11 percent of patients receiving placebo.
IP: Logged |
posted
I wasn't it DNDN anymore, and I haven't been watching it lately.
I see that this bad news came out in the pre-market. So am I correct that anyone who had a stop-loss order would have been screwed because it went down in pre-market. Is there a good reason for companies to release after or before regular market hours? Seems kind of unfair.
I'm just trying to learn.
Jo
-------------------- "Great Day for Up!"....Dr. Seuss
IP: Logged |
posted
Jo, someone else can probably answer more definitively, but I think news like this has to be released when the market is closed. I think if news like this is released during the day, they will halt the stock until the info is disseminated (sp) to everyone.
IP: Logged |
posted
That stinks since you can only place limit orders in extended hours. Therefore, you cannot protect yourself with a stop-loss.
This happenned to me with another stock when earnings were released after-hours. Went past my stop loss point by the time the market opened the next day.
I guess with a stock like DNDN, if you were in it, you'd need to constantly monitor it even after hours!
Jo
-------------------- "Great Day for Up!"....Dr. Seuss
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Roll Eyes]](rolleyes.gif)
![[Smile]](smile.gif)
![[Eek!]](eek.gif)
